Background: There are different types of Coronavirus disease (COVID-19) vaccines available presently, and their emergency use has been approved by WHO worldwide on a mass scale. COVID-19 vaccine breakthrough infections have been reported worldwide. In Pakistan, there are limited data on COVID-19 vaccine breakthrough infections and their clinical course, especially in healthcare professionals (HCPs). Our study aims to investigate COVID-19 infections among vaccinated HCPs. Methods: A prospective study was conducted on 425 healthcare professionals. Data collected from healthcare professionals included names, age, gender, number of vaccination doses, COVID-19 infection pre and post-vaccination, the severity of COVID-19 infection (if positive), and co-morbid conditions. Ethical board approval was taken. Statistical Package for Social Sciences (SPSS) version 23 (IBM Corp., Armonk, NY) was used to analyze the data. Results: After complete vaccination, 17.27% acquired COVID-19 infection; 2.47% had COVID-19 infection both pre and post-vaccination. The mean age was 32.46 years (n=71) with a standard deviation of ±9.376. The male to female ratio was 1.53. COVID-19 PCR was positive in 95.77%. During the course of the disease, 4.2% were asymptomatic, 92.95% had mild symptoms, 1.4% were hospitalized, and 1.4% had to be managed in the intensive care unit. None of the HCPs who had received booster doses acquired a COVID-19 infection. Conclusion: It was found that prior COVID-19 infection and vaccination do not confer immunity from infection. However, proper vaccination limits the severity, morbidity, and mortality of COVID-19 infection.
IntroductionDiabetes mellitus is a syndrome affecting more than 28.7 million people worldwide and its prevalence in Pakistan is reported to be about 11%. Management includes lifestyle changes and varied therapeutic regimens. Metformin (MET) alone and in combinations is considered as an important agent for glycemic control. Our study is based on MET combination therapy with empagliflozin versus sitagliptin in order to achieve glycemic control. MethodsThis randomized clinical trial was conducted in the Department of Medicine and Allied of Federal Government Polyclinic Hospital, Islamabad, from January 2022 till June 2022. The ethical approval letter numbered FGPC. 1-1/2022/Ethical Committee was taken before the commencement of the trial. The patients were divided into group A and group B. All patients were given MET 1000mg twice a day. Group A patients were additionally given sitagliptin 50mg twice daily whereas Group B patients were additionally given empagliflozin 10mg once daily. Glycemic control was documented with HbA1c at the start of treatment and after three months of treatment in both groups. A proforma was used to collect data. Analysis of the data was performed using the Statistical Package for the Social Sciences version 17 (SPSS Inc., Chicago, USA). ResultsA total of 126 patients were included in the study with a mean age of 53.53 ± 6.49. 81.7% were males while 18.3% were females. The mean reduction in HbA1c from baseline in group A was -0.81 ± 0.19% and in group B was -1.13 ± 0.24% with statistically significant p-value (p-value = 0.000). ConclusionEmpagliflozin in combination with metformin is more efficacious in maintaining glycemic control as compared to sitagliptin in combination with metformin.
Introduction: Helicobacter pylori ( H. pylori ) colonization is prevalent all over the world, and it is associated with low socioeconomic status, poor hygiene, and overcrowding. Its eradication is important since it is an etiologic agent for gastritis, peptic ulcer, gastric carcinoma, and mucosa-associated lymphoid tissue lymphoma. Different regimens are available for the eradication of H. pylori and include triple therapy and sequential therapy. Our study aims to compare the efficacy of triple therapy versus sequential therapy in the eradication of H. pylori . Material and methods: This randomized clinical trial was conducted at the Pakistan Institute of Medical Sciences Hospital, Islamabad, from September 2016 to September 2017 after the approval of the institutional review board. A total of 160 patients were enrolled and equally divided into two, group A and group B. A twice-daily dose of amoxicillin 1,000 mg, rabeprazole 20 mg, and clarithromycin 500 mg was given to group A for 10 days, while group B was initially given rabeprazole 20 mg and amoxicillin 1,000 mg two times daily for the first five days (i.e., induction phase), followed by triple therapy that included rabeprazole 20 mg, clarithromycin 500 mg, and metronidazole/tinidazole 500 mg twice daily for the next five days. A negative stool antigen test performed four weeks after the completion of therapy was considered an effective eradication. A proforma was used to collect data that included age, gender, city or province of residence, family income, group (group A or group B), and eradication efficacy. Analysis of the data was performed using the Statistical Package for the Social Sciences version 17 (SPSS Inc., Chicago, USA). Results: A total of 160 patients were included, with mean age and standard deviation of 40.02±24.4 years. The male/female ratio was 1.8:1. Successful eradication of H. pylori achieved in group A was 67.5% (N=54) in comparison to group B, which was 95% (N=76) (p=0.001). Conclusion: Sequential therapy was superior to triple therapy in H. pylori eradication.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.